Table 4.

Adverse events during hospitalisation according to study groups

Adverse event	Simvastatin n=19	Placebo n=15	p Value
AST level, median (IQR), (ukat/L)	0.25 (0.22–0.36)	0.7 (0.3–0.94)	0.08
AST>2 times upper reference limit	1 (5.2%)	3 (20%)	0.30
ALT level, median (IQR), (ukat/L)	0.28 (0.22–0.43)	0.68 (0.3–1.0)	0.19
ALT>2 times upper reference limit	2 (10.5%)	2 (13.3%)	1
CK level, median (IQR), (ukat/L)	0.87 (0.51–2.22)	0.60 (0.32–2.7)	0.53
CK>2 times upper reference limit	1 (5.2%)	1 (6.6%)	1

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase.